-
Ferring and PharmaBiome enter into a new microbiome R&D collaboration and exclusive licensing agreement
inFerring and PharmaBiome enter into a new microbiome R&D collaboration and exclusive…
-
New data show durable response following treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
in…
-
-
-
Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
inAd hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals appoints new…
-
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
inFour Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the…
-
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
inFerring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in…
-
Ferring announces abstract of the first prospective, multi-national, real-world study of Rekovelle® (follitropin delta) at the congress of the Pacific Society for Reproductive Medicine
inFerring announces abstract of the first prospective, multi-national, real-world study of Rekovelle®…
-
Approval of new medicines in 2022 sets Ferring on course for future growth and diversification
inApproval of new medicines in 2022 sets Ferring on course for future…
-
Ferring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer
inFerring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer…
PRESS RELEASE 2023
PRESS RELEASE 2023